We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that Regeneron has terminated the option and license agreement collaboration between the companies.
The rate of filled opioid prescriptions is increasing for all types of incisional ocular surgery, according to a study published online Sept. 19 in JAMA Ophthalmology.
Ocular Therapeutix Announces FDA Approval of Dextenza (dexamethasone intracanalicular insert) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery.